banner
Home / Products / Antidiabetic
Products
API Nateglinide Powder Antidiabetic Nateglinide Powder Raw Material Nateglinide

API Nateglinide Powder Antidiabetic Nateglinide Powder Raw Material Nateglinide

Overview API Nateglinide powder Antidiabetic Nateglinide powder Raw Material Nateglinide Product Description Product Dat
Overview
Basic Info.
Model NO. D-sung-Nateglinide
CAS No 105816-04-4
MW 317.42258
Test Method HPLC
Specific COA
Melting Point 137
Density 1.104
Boiling Point 527.6
Mf C19h27no3
Grade Pharmaceutical Grade
Color White Color
Application Pharmaceutical
Assay HPLC 99%
Name Nateglinide Powder
Appearance White Powder
Product Name Nateglinide
Transport Package Negotiable
Specification 99%
Trademark D-Sung
Origin Xi′an Shaanxi
Production Capacity 5000kg/Month
Product Description

API Nateglinide Powder Antidiabetic Nateglinide Powder Raw Material Nateglinide

API Nateglinide powder Antidiabetic Nateglinide powder Raw Material NateglinideProduct Description

API Nateglinide Powder Antidiabetic Nateglinide Powder Raw Material Nateglinide

API Nateglinide Powder Antidiabetic Nateglinide Powder Raw Material Nateglinide

Product Datails

API Nateglinide Powder Antidiabetic Nateglinide Powder Raw Material Nateglinide

Product NameNateglinide
CAS:105816-04-4
MFC19H27NO3
Molecular Wegiht:317.42262-145-8
Nateglinide is an oral antihyperglycemic agent used for the treatment of non Diabetes drug API Nateglinide/trans-d-phenylalanine CAS 105816-04-4dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting secretagogues, which act by binding to β cells of the pancreas to stimulate release. Nateglinide is an amino acid derivative that induces an early response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.Application&Function

API Nateglinide Powder Antidiabetic Nateglinide Powder Raw Material Nateglinide

1. Nateglinide is used for the treatment of the form of diabetes mellitus that appears most frequently in adulthood -- known as type 2 or non-insulin-dependent diabetes -- that cannot be managed by exercise and control of diet alone.2. Nateglinide may be added to diet and exercise to manage the disease, or it may be combined with metformin when diet, exercise, and either drug alone cannot provide adequate control of blood sugar.Specification